![](/img/cover-not-exists.png)
Cost-Utility Analysis of Pazopanib Verse Sunitinib as First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC) iN Spain
Espinosa, J., González-Larriba, J,L., Maroto, P., Méndez-Vidal, M.J., Díaz-Cerezo, S.Volume:
17
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2014.08.2265
Date:
November, 2014
File:
PDF, 86 KB
english, 2014